Please assess the completion status of the following clinical trial:

Trial Title: Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age of 18 - 85 years~* Male and Female patients (females of child bearing potential must be using adequate contraceptive precautions)~* CHF (symptoms and/or sign of CHF, ejection fraction \< 40% (HfrEF) 14 or symptoms and/or signs of CHF, ejection fraction 40-49 % and NT-pro BNP \> 125 pg/ml, and at least one structural abnormality of left atrium or ventricle (HFmEF) 14 in stable conditions.~* Females of childbearing potential or within two years of the menopause must have a negative urine pregnancy test at screening visit.~* Informed consent has to be given in written form.~Exclusion Criteria:~* Any other form of diabetes mellitus than type 2 diabetes mellitus~* Use of insulin or any SGLT-2 inhibitor within the past 10 weeks prior to the screening visit (visit 1).~* Patients with more than two blood glucose lowering medications~* Uncontrolled diabetes (fasting plasma glucose ≥ 240 mg/dl, HbA1c ≥ 10%)~* Any history of stroke, transient ischemic attack, instable angina pectoris, or myocardial infarction within the last 6 months prior to study inclusion~* Estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73m² (following the inclusion criteria of EMPA-REG OUTCOME study 1-3)~* Chronic heart failure NYHA stage IV~* Use of loop diuretics above furosemide \> 80 mg/day, or torasemide \>40 mg/day, or piretanide \> 6 mg/day~* Implanted pacemakers or defibrillators~* Any other relevant clinical contraindication of MRI examination~* Uncontrolled arterial hypertension (i.e. ≥ 180/110 mmHg)~* Severe disorders of the gastrointestinal tract or other diseases which interfere with the pharmacodynamics and pharmacokinetics of study drugs~* Significant laboratory abnormalities such as Serum Glutamate-Oxaloacetate-Transaminase (SGOT) or Serum Glutamate-Pyruvate-Transaminase (SGPT) levels more than 3 x above the upper limit of normal range

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Oral Tablet (Type: PLACEBO_COMPARATOR): Patients will be randomized to empagliflozin 10 mg orally once daily or one placebo tablet orally once daily.
- Empagliflozin (Type: ACTIVE_COMPARATOR): Patients will be randomized to empagliflozin 10 mg orally once daily or one placebo tablet orally once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).